

1 **A fast and sensitive absolute quantification assay for the detection of**
2 **SARS-CoV-2 peptides using Parallel Reaction Monitoring Mass**
3 **Spectrometry**

4
5 Akshada Gajbhiye^{1#}, Atakan Nalbant^{1#}, Tiaan Heunis^{1#}, Frances Sidgwick^{1#}, Andrew
6 Porter^{1#}, Yusri Taha², Matthias Trost^{1*}

7 ¹Laboratory for Biomedical Mass Spectrometry, Newcastle University, Newcastle upon
8 Tyne, UK; ²The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon
9 Tyne, Newcastle upon Tyne NE1 4LP, UK.

10

11 [#]these authors contributed equally

12 *Correspondence: Matthias Trost email: matthias.trost@ncl.ac.uk

13

14

15

16 **Running title:** COVID-PRM

17 **Keywords:** SARS-CoV-2, PRM, Absolute Quantification, Mass Spectrometry

18

19

20

21 **ABSTRACT:**

22 The on-going SARS-CoV-2 (COVID-19) pandemic has called for an urgent need for rapid
23 and high-throughput methods for mass testing for early detection, prevention and surveillance
24 of the disease. Here, we tested if targeted parallel reaction monitoring (PRM) quantification
25 using high resolution Orbitrap instruments can provide the sensitivity and speed required for
26 a high-throughput method that could be used for clinical diagnosis. Here we report a high-
27 throughput and sensitive PRM-MS assay that enables absolute quantification of SARS-CoV-
28 2 nucleocapsid peptides with short turn-around times. Concatenated peptides (QconCAT)
29 synthesized using isotopically labelled SARS-CoV-2 were used for absolute quantification.
30 We developed a fast and high-throughput S-trap-based sample preparation method, which
31 was then successfully utilized for testing 25 positive and 25 negative heat-inactivated
32 nasopharyngeal swab samples for SARS-CoV-2 detection. The method was able to
33 differentiate between negative and positive patients accurately within its limits of detection.
34 Moreover, extrapolating from the QconCAT absolute quantification, our data show that
35 patients with Ct values as low as 17.5 have NCAP protein amounts of around 7.5 pmol in
36 swab samples. The present high-throughput method could potentially be utilized in
37 specialized clinics as an alternative tool for detection of SARS-CoV-2.

38
39
40
41

42 INTRODUCTION:

43 The on-going human Coronavirus Disease 2019 (COVID-19) pandemic caused and still
44 causes severe global health and economic problems in almost every country in the world.
45 Since the beginning of the pandemic till March 2022, Covid-19 has affected more than 450M
46 people and caused 6 M deaths worldwide [1]. The disease is caused by severe acute
47 respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel and more virulent strain of
48 coronaviruses (CoVs) [2]. This strain of coronavirus is more virulent but similar to two other
49 strains of betacoronaviruses SARS-CoV and Middle East respiratory syndrome (MERS-CoV)
50 [3]. Like other CoVs, the SARS-CoV-2 genome comprises of linear, single-stranded positive-
51 sense RNA which encodes 10 genes, responsible for production of total 26 proteins. Out of
52 the 26 proteins, four structural proteins contribute to ~80% of the genome. These four
53 structural proteins comprise of a spike glycoprotein (S), which enables viral entry into the
54 mammalian cell by binding to the angiotensin-converting enzyme 2 (ACE2) receptor, a
55 nucleoprotein (N) that provides stability to the viral genome by directly binding to the RNA,
56 an envelope protein (E) and membrane protein (M) that forms the outer layer of the virus [4].
57 The N and S protein copies per virion are estimated to be approximately 1000 and 300,
58 respectively. The remaining proteins of the genome are required for functions such as
59 proofreading, RNA polymerase, proteases and other supporting proteins for replication of the
60 genome.

61 The predominant method of testing for individuals infected with SARS-CoV-2 includes real-
62 time quantitative polymerase chain reaction (RT-qPCR), which is usually done on
63 nasopharyngeal (NP) swabs. The RNA is extracted from these swabs and amplified using
64 specific primers, which makes it more specific, sensitive and relatively rapid, deeming it as
65 the gold standard assay for SARS-CoV-2 detection by World Health Organization (WHO).
66 Other rapid tests including Simple Amplification Based Assay (SAMBA) [5], which uses
67 nucleic acid for detection, serological assays such as Lateral Flow Immunoassays (LFA) [6]
68 and enzyme-linked immunosorbent assays (ELISA) have also been developed. These have
69 been implemented owing to the global pressure for identifying the infected individuals with
70 quick turnaround rates. The high demand for RT-qPCR testing has in recent times caused a
71 global shortage of reagents as well as other rapid tests are prone to false-positive and false-
72 negative reporting which might be caused due to inhibition of substances in clinical samples
73 [7]. Thus, at times during the pandemic, complementary alternative assays for detection of

74 SARS-CoV-2 became increasingly urgent to share the burden of immediate mass testing
75 required for management of the pandemic.

76 In recent years mass spectrometry (MS)-based targeted proteomic approaches have
77 increasingly been implemented in clinical labs due to advancements in the sensitivity and
78 accuracy of instrumentation. An excellent example of this is successful application of Matrix-
79 Assisted Laser Desorption/Ionization Time-Of-Flight mass spectrometry (MALDI-TOF-MS)
80 for characterization of Nucleoprotein (NCAP) and Spike Glycoprotein (SPIKE) from the
81 SARS virus, which caused an outbreak in 2003[8]. Building on this, many MS-based
82 methods have emerged for detection of the SARS-CoV-2 NCAP, and SPIKE proteins based
83 on their tryptic peptides. Most of these methods either have been built directly from
84 specimens infected with high viral loads of SARS-CoV-2; for instance, a study by Gouveia
85 *et al* selected 14 peptides from proteomics of SARS-CoV-2 infected Vero cells [9], or from
86 clinical specimens where enrichment was required for detection of these peptides. Ihling *et al*
87 used gargle solution for detection of SARS-CoV-2 peptides from three Covid-19 positive
88 individuals [10]. In another study by Nikolaev *et al*, peptides from NCAP protein were
89 detected by tandem mass spectrometry using nasopharyngeal epithelial scrapings [11].
90 Similarly, Singh *et al* [12], Gouveia *et al* [13] and Saadi *et al* [14] utilized nasopharyngeal
91 swabs to establish proof-of-principle studies for detection of SARS-CoV-2 peptides. More
92 recently Renuse *et al* [15] present a LC-MS based method where peptides for NCAP and
93 SPIKE were enriched using immunoaffinity beads. Puyvelde *et al* [16] have attempted to use
94 a QconCAT Stable Isotopic Labeled (SIL) internal standard for improving the efficiency of
95 their MRM-MS assay. Importantly, most of these methods include acetone precipitation-
96 based methods for sample preparation and are either low-throughput or time consuming,
97 thereby lacking the short turn-around time required for a clinical high-throughput assay.

98 In this study, we report development of a high-throughput liquid chromatography mass
99 spectrometry based parallel reaction monitoring (PRM) assay for detection and absolute
100 quantification of SARS-CoV-2 peptides, which allows viral detection directly from patient
101 samples. We could identify and report patients with high viral load and Ct values up to 22.
102 This method allows detection of SARS-CoV-2 peptides with a turnaround time of ~2 hrs for
103 each patient starting from sample preparation to reporting the results and up to 200 samples
104 per day.

105 **MATERIALS AND METHODS:**

106 **Chemicals and reagents:**

107 Sodium dodecyl sulfate (SDS), >98% pure was purchased from VWR International Limited.
108 Triethylammonium bicarbonate (TEAB) 1 M, and ortho-phosphoric acid 85%, Tris(2-
109 carboxyethyl) phosphine (TCEP) and Iodoacetamide \geq 98% were purchased from Sigma.
110 Proteomics Grade Trypsin was purchased from Pierce Thermo Fisher Scientific. Acetonitrile,
111 Methanol (LC-MS grade) and Formic Acid (>99.0%, LC-MS, UHPLC-MS) were purchased
112 from Fisher Scientific. Formic acid was obtained from Merck. S-traps were purchased from
113 Protifi. SARS-CoV-2 Spike Glycoprotein (Full-Length) expressed in CHO cells from Native
114 Antigen, Synthetic Sputum from LGC and PolyQuant Cov-MS from PolyQuant were
115 received as part of the Covid Moonshot Consortium. SARS-CoV-2 Nucleoprotein was
116 received from University of Sheffield.

117 **Patient samples for method validation:**

118 Fifty nasopharyngeal swab samples including both positive and negative for Covid-19, were
119 received from the Newcastle Upon Tyne Hospitals NHS Foundation Trust, in 2.5 mL VTM.
120 The samples were stored at -20°C until further processing.

121 **Sample pre-processing and preparation for MS:**

122 The SARS-CoV-2 recombinant protein standards were processed for peptide identification,
123 targeted MS-based proteomic method development, and calibration curve establishment for
124 sensitivity assessment. Each protein standard was processed separately by suspension
125 trapping (S-Trap), with minor modifications as previously described [17,18], for method
126 development and peptide identification. Modifications included a single step reduction and
127 alkylation with 10 mM TCEP and IAA, respectively, and digestion at 47 °C for 1 hour using
128 a 1:10 trypsin: protein ratio. The method was further optimized to exclude the reduction and
129 alkylation step, as well as sample elution, to achieve a faster and high-throughput method
130 discussed further in the results section.

131

132

133 **LC-MS Method and data analysis:**

134 LC-MS/MS analysis was performed on a Thermo Scientific QExactive-HF (QE-HF) hybrid
135 mass spectrometer coupled to a Evosep One LC device. The Evosep One was operated using
136 the 200 samples per day method at a flow rate of 2 $\mu\text{l}/\text{min}$ with a 7.2-minute total run time
137 per sample [19]. The Evosep One was equipped with a 40 mm x 150 μm column from
138 Evosep packed with Dr Maisch C18 AQ, 1.9 μm beads. The QE HF was operated in either
139 DDA or PRM-mode using a resolution of 60,000 AGC target of 2×10^5 for DDA and 30,000
140 for PRM, maximum injection time of 50 ms, and a quadrupole isolation width of 1.2 m/z.
141 Peptides were selected for MS/MS data acquisition using an un-scheduled method and
142 fragmented using collision energies optimised for each peptide. An electrospray voltage of
143 2.1 kV and capillary temperature of 300°C, with no sheath and auxiliary gas flow, was used.
144 MaxQuant 1.6.10.43 was used for peptide and protein identification [20] using
145 UniprotKB/Swissprot databases for Homo Sapiens containing 42437 sequences downloaded
146 on September 2020 and a combined viral database SARS and influenza viruses including the
147 SARS-Cov-2 virus sequences. Targeted proteomic method refinement and data analysis was
148 performed in Skyline-daily 20.2.1.286 [21].

149 **Determination of LOD and LOQ:**

150 Calibration curves for LOD and LOQ determination were obtained from SARS-CoV-2
151 NCAP peptides in 0.1% formic acid, synthetic sputum, swab and saliva samples. To generate
152 the calibration curves in different matrices, proteotypic peptides for NCAP were spiked into
153 each matrix at 10 fmol/ μL followed by serial dilution (2-fold) until 10 attomoles/ μL was
154 reached. For each concentration, 5 μL sample was injected on the LC-MS system in
155 triplicates A calibration curve was created using the raw intensity values for each peptide in
156 each matrix and a regression value (R^2) was calculated. Limits of detection and quantitation
157 were determined using the standard deviation of the curve and the slope values.

158 **Patient sample pre-processing for MS analysis:**

159 Nasopharyngeal swab samples were received in 2.5 mL of Viral Transport Medium(VTM),
160 comprising of Anderson's modified Hanks Balanced Salt Solution (8.0 g/L NaCl, 0.4 g/L
161 KCl, 0.05 g/L Na_2HPO_4 , 0.06 g/L KH_2PO_4 , 1.0 g/L Glucose, 0.7 g/L NaHCO_3 , 0.2 g/L
162 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.14 g/L $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$) with 2% v/v heat-inactivated fetal bovine serum,

163 100 µg/mL gentamicin and 0.5 µg/mL amphotericin B, as recommended by the CDC
164 [22].The virus was inactivated by heating at 80°C for 5 min and 1 mL of 20% SDS was
165 added to the VTM containing the swab such that the total SDS concentration was ~5 % which
166 is compatible with the S-trap method of sample digestion. The samples were vortexed for 15
167 min followed by centrifugation at 1500 x g and the entire solution was collected, aliquoted
168 and stored at -80°C for further use.

169 **RESULTS**


170

171 A high-throughput LC-MS method should be reproducible, robust and sensitive. Towards our
172 goal of developing a high-throughput PRM method for detection of SARS-Cov-2 peptides,
173 we developed a fast and reproducible sample preparation method which can be used in
174 conjunction with the PRM method. The details of the of the sample preparation and LC-MS
175 method are listed below.

176

177 **Sample preparation for high-throughput analysis of SARS-CoV-2 samples**

178 The sample preparation was designed to accommodate nasopharyngeal swabs which are the
179 preferred sample collection methods in use in the clinic. In order to return clinical data
180 quickly, we aimed to design the sample preparation method for high-throughput sample
181 preparation, efficient virus inactivation and analysis within 2 hrs (**Figure 1**).



182

183 **Figure 1: A stepwise detailed workflow for high-throughput sample processing for LC-**
184 **MS based detection of SARS-CoV-2 peptides.** 20% SDS was added to nasopharyngeal
185 swab or saliva samples from patients for a final concentration of 5%. Fifty uL of the 3 mL
186 sample were added onto 96-well S-Trap plates, where the samples were washed, digested,
187 and eluted in a mass spectrometry compatible buffer. The eluates were directly separated on

188 an EvoSep LC system and analysed on a QExactive HF mass spectrometer. The present
189 method allows efficient digestion of multiple samples with various matrices under 2 hours,
190 permitting the LC-MS and data analysis in approximately 15 mins.

191


192 Recombinant SARS-CoV-2 SPIKE and NCAP proteins were spiked at 100 pmol/mL into
193 artificial saliva or into saliva and swab samples (stored in 3 mL viral transfer medium) taken
194 from a healthy volunteer. As clinical samples will require virus inactivation, we tested 70 %
195 ethanol, heat inactivation at 80°C for 5 min as well as addition of 20% SDS to a final
196 concentration of 5% followed by heat inactivation at 80°C. After addition of ethanol or SDS,
197 the samples were shaken for 15 mins and centrifuged for 5 mins at 1500 x g. Samples were
198 further processed using 96-well S-trap plates as this workflow provides a fast method for
199 digestion of proteins in most buffers without the need for precipitation, thereby avoiding
200 sample loss and long sample preparation times. As none of the previously reported
201 proteotypic peptides of NCAP or SPIKE contain a cysteine, we tested if reduction with TCEP
202 and alkylation with IAA were necessary for the efficient detection of the target peptides.
203 Digestion efficiency was assessed by LC-MS/MS analysis of tryptic peptides and was found
204 to be unaffected even when samples were not reduced and alkylated before digestion.
205 **(Supplementary Figure 1A).**

206 In the standard S-Trap protocol peptides are eluted with two aqueous (50 mM TEAB and
207 0.2% formic acid) and an organic (50% MeCN, 0.2% formic acid) step. Due to the organic
208 solvent, the samples require vacuum drying before LC-MS analysis. In order to save time, we
209 tested if we could omit the elution in MeCN, thereby allowing straight injection of the eluted
210 digests into the mass spectrometer. Indeed, omission of the organic elution did not affect
211 overall intensities of SPIKE and NCAP peptides **(Supplementary Figure 1B).**

212 **Identification of SARS-CoV-2 proteotypic peptides for targeted analysis**

213 Selection of appropriate, proteotypic peptides is a key step towards developing a robust and
214 reproducible targeted LC-MS assay. In order to identify the proteotypic peptides of SARS-
215 CoV-2 SPIKE and NCAP proteins, recombinant proteins were digested in neat (0.1% formic
216 acid) and spiked into artificial saliva or into saliva and swab samples taken from a healthy
217 volunteer. Digests were analysed on a Q-Exactive HF in data-dependent analysis (DDA)
218 mode coupled to an EvoSep LC -MS system, using the 60 sample per day (60 SPD) method
219 **(Figure 2).** The DDA-based analysis of neat SPIKE and NCAP recombinant proteins

220 revealed a list of tryptic peptides (**Supplementary Data 1**), which provided the basis for
 221 initial screening of the target peptides. Furthermore, a QconCAT for stable isotope labelling
 222 based absolute quantification was added. This QconCAT was synthesized to include specific
 223 SPIKE and NCAP peptides based on the study by Puyvelde et al. [16]. Finally, DDA analysis
 224 of saliva samples revealed a list of consistently identified proteotypic peptides from high-
 225 abundant human proteins such as Lysozyme C (LysC) which we used as an internal control to
 226 check for sample preparation and acquisition efficiency (**Supplementary Data 2**).
 227



228

229 **Figure 2: High-throughput and fast PRM-MS method for detection of SARS-CoV-2**
 230 **peptides using state-of-the art LC-MS set-up.** Recombinant protein standards for SPIKE and
 231 NCAP were utilized in neat, simulated sputum, saliva and nasopharyngeal swabs for developing a fast
 232 and high-throughput PRM method using 96-well S-trap sample preparation and an Evosep coupled to
 233 Thermo QE-HF mass spectrometer. Data was analysed by Skyline to assess the sensitivity of the
 234 system as well as to validate using patient swab samples.

235 In order to select optimal proteotypic peptides for the targeted PRM analysis, we followed
 236 published selection criteria for a targeted-based LC-MS assays such as tryptic peptide length
 237 of 8 to 25 amino acid and excluded peptides with possible modifications such as oxidation on
 238 Methionine, deamidation on Asparagine followed by Glycine, and any other possible post-
 239 translational modifications [24]. Following these criteria, an initial list of tryptic peptides was

240 generated which were further analysed in matrices such as saliva. Of the initial 19 peptides
241 (**Supplementary Data 3**), only five could reproducibly be detected when analysed in a
242 background matrix of artificial and volunteer saliva. As peptides from SPIKE were
243 inconsistently observed and their retention times varied across runs, SPIKE peptides were
244 omitted from future analysis. SPIKE peptides are known to be heavily glycosylated, making
245 them notoriously harder to detect [25]. Moreover, NCAP is considered to be about 3-fold
246 more abundant in SARS-CoV-2 than SPIKE [4], increasing the sensitivity. Therefore, it was
247 not surprising that the highest sensitivity was achieved for the NCAP peptides
248 AYNVTQAFGR and ADETQALPQR. Additionally, as KADETQALPAR was consistently
249 detected in all the DDA runs, it was included in the list even though it contains a missed
250 cleavage. Human Lysozyme C, as mentioned earlier, was used as an internal control for
251 sample preparation and to check for digestion and ionization efficiency. The final list
252 consisted of total seven peptides including the stable isotopically labelled peptides from
253 QconCAT which were further used for MS method development and optimization (**Table 1**).

254 **PRM-MS method development and optimization**

255 A PRM method was created on the QE-HF using the 200 samples per day (200 SPD) short
256 gradient LC method integrated on the Evosep One. The Evosep One is specifically designed
257 to run samples back-to-back without carryover due to the tip-based sample injection system,
258 which serves as a single-use trap column thereby increasing the overall life of the column,
259 making the system well-suited for a high-throughput method [26]. The PRM method was
260 further optimized for collision energies (**Supplementary Figure 2**) for the individually
261 selected peptides along with their corresponding SIL peptides emerging from the QconCAT.
262 The QconCAT sequence information can be found in (**Supplementary Data 4**). The
263 normalized collision energies (NCE) for the targeted peptides were optimized within the
264 range of 20- 29 for all the peptides. The optimal collision energies for individual peptides
265 were selected based on the intensities of their product ions using Skyline. Details of the seven
266 peptides and collision energies used for the final PRM assay are listed in **Table 1**.

267

268 **Table 1: Peptides selected for the development of PRM-MS assay for detection of**
269 **SARS-CoV-2 peptides**

| No | Peptide Sequence | Source | m/z, charge | Norm. Collision Energy | Type |
|----|------------------|-------------------------------|-----------------------|------------------------|-------|
| 1 | AYNVTQAFGR | NCAP(SARS-CoV-2) | 563.785 ²⁺ | 24 | light |
| 2 | ADETQALPQR | NCAP(SARS-CoV-2) | 564.785 ²⁺ | 23 | light |
| 3 | KADETQALPQR | NCAP(SARS-CoV-2) | 419.557 ³⁺ | 20 | light |
| 4 | AYNVTQAFGR | QconCAT | 571.263 ²⁺ | 24 | heavy |
| 5 | ADETQALPQR | QconCAT | 572.263 ²⁺ | 23 | heavy |
| 6 | KADETQALPQR | QconCAT | 425.207 ²⁺ | 20 | heavy |
| 7 | STDYGIFQINS | LYS-C (<i>Homo sapiens</i>) | 700.843 ²⁺ | 25 | light |


270

271 **Assessing the sensitivity and robustness of the PRM method**


272 The next step in establishing the high throughput PRM method involved its assessment for
273 sensitivity and specificity. Calibration curves of the target peptides in neat, artificial saliva as
274 well as real saliva and swab samples were generated using the tryptic digests for recombinant
275 protein standards for NCAP. Recombinant tryptic peptides in 0.1% formic acid (“neat”)
276 (**Figure 3A**), spiked swab (**Figure 3B**), spiked oral fluid (**Figure 3C**) and spiked saliva
277 (**Figure 3D**) were injected in a dilution series from 50 femtomoles to 50 attomoles was on
278 column. The limit of detection (LOD) for NCAP peptides was found to be as low as 170 amol
279 on column, while the limit of quantitation (LOQ) was found to be 850 amol when injected
280 neat (**Table 2**). The calibration curves for the logged intensities also depict the linearity of the
281 curves as seen in (**Supplementary Figure 3**). The LOD and LOQ were calculated using the
282 formulae $3 \cdot Sa/b$ and $10 \cdot Sa/b$ respectively, where Sa is standard deviation of the calibration
283 curve response and b is the slope of the curve. The LOD and LOQ decreased to 0.63 fmol and
284 3.24 fmol on column, respectively, for the same peptide when injected as a spike-in in the
285 real saliva and swab samples. The drop in sensitivity was expected when peptide standards

286 were injected with saliva sample due to the matrix effect contributed by other endogenous
287 high abundant salivary proteins such as Lysozyme C and Albumin. The high abundance of
288 these proteins contributes towards signal suppression of the target peptides resulting in the
289 overall drop in sensitivity in the saliva and swab samples.

290 The existing PRM assay system needed to not only be sensitive but also robust to
291 carryout high-throughput analysis of many samples. To test the robustness of the LC-MS
292 system a continuous 200 sample test was performed with a saliva sample spiked-in with
293 NCAP peptides. The peptide AYNVTQAFGR was monitored for its product ion areas and
294 retention time. The test revealed that the system performed consistently without a notable
295 drop in sensitivity across all 200 samples, solidifying the stability of the system to handle
296 such a load (Figure 4A and 4B).



298 **Figure 3: Calibration curves for estimating the limits of detection (LOD) and quantitation**
299 **(LOQ).** Tryptic peptides generated from recombinant SARS-CoV-2 NCAP standard protein were
300 injected on the LC-MS system to generate calibration curves starting from 50 fmol on column and
301 diluted 2-fold until 48 amol was achieved either in 0.1% formic acid as depicted in figure A. Figures
302 B, C and D represent the drop in sensitivity of the LOD and LOQ when injected as a spike-in in a
303 swab, oral fluid or saliva sample respectively. The sensitivity of the system was assessed based on the
304 three peptides AYNVTQAFGR, ADETQALPQR and KADETQALPQR selected for final PRM
305 method. The figures in the inset are the zoomed areas of the lower concentration data points.



306

307 **Figure 4: Testing the robustness of the LC-MS assay.** To test the stability and robustness of the
308 existing PRM method, a stress test with 200 consecutive injections of saliva spiked with neat NCAP
309 peptides was conducted where figure A depicts overall consistent peak area percentage for all the 6
310 transitions for the NCAP peptide AYNVTQAFGR. Figure B depicts the intensity and retention time
311 variation of the same peptide over 200 injections.

312

313

314 **Table 2: Limits of detection and quantitation calculated for NCAP peptides on the existing LC-**
 315 **MS system in various matrices are represented below**

| Protein | Matrix | Peptide | LOD (fmol on column) | LOQ (fmol on column) | |
|----------------|-------------------|----------------|-----------------------------|-----------------------------|------|
| NCAP | 0.1% Formic acid | AYNVTQAFGR | 0.17 | 0.85 | |
| | | ADETQALPQR | 0.37 | 1.1 | |
| | | KADETQALPQR | 0.26 | 1.3 | |
| | Artificial sputum | AYNVTQAFGR | 1.6 | 8.0 | |
| | | ADETQALPQR | 0.66 | 3.3 | |
| | | KADETQALPQR | 6.3 | 32.1 | |
| | Spiked Saliva | AYNVTQAFGR | 2.6 | 12.8 | |
| | | ADETQALPQR | 4.7 | 23.6 | |
| | | KADETQALPQR | 7.3 | 36.4 | |
| | | Spiked Swab | AYNVTQAFGR | 1.5 | 7.2 |
| | | | ADETQALPQR | 3.0 | 14.8 |
| | | | KADETQALPQR | 4.4 | 21.9 |

316

317 **Validation of PRM Assay using 50 patient samples**


318 The final PRM method was validated using 25 positive and 25 negative patient samples. The
 319 samples had been analysed by either RT-PCR, SAMBA II or LumiraDx. RT-PCR provided a
 320 Cycle Time (Ct) value and any Ct <40 was considered as positive. The Simple
 321 AMplification-Based Assay (SAMBA) II nucleic acid testing system (SAMBA II) finds
 322 traces of viral genetic material and amplifies it a billion times [28] and LumiraDx is a
 323 microfluidic immunofluorescence assay for qualitative detection of nucleocapsid protein
 324 antigen [29]. The latter two methods do not provide a quantitation of viral load.

325 The samples were processed according to the optimized sample preparation protocol. BCA
 326 estimation of the samples revealed that the total concentration of the protein in the extraction
 327 buffer ranged between 3-5 mg/mL. Out of the total sample extracted from swab in 3 mL of
 328 VTM with 5% SDS buffer, only 50 µL sample (~200 µg) was taken for processing. ~10 µg
 329 sample was injected on column, where concentration of QconCAT in the sample was 10 fmol
 330 on column. Thus, ~1/1200th of the total sample was used for detection of the SARS-CoV-2
 331 peptides using the present method.

332 The samples were attributed as positive only if they passed the following criteria: (i) At least
 333 two out of maximum six fragment ion transitions were detectable and (ii) The retention times
 334 matched that of the heavy QconCAT counterpart of the same peptide. The peptides that were

335 assigned as positive were then used for calculation of the probable absolute concentration
 336 from the total H/L ratios calculated by Skyline software.

337 Our PRM method was able to detect nine positive cases, three shown here and the
 338 other six in (Supplementary Figure 4), out of the 25 positive samples correctly (Figure 5),
 339 suggesting that patients with high viral load can be detected with this method. LUMIRA,
 340 qPCR and SAMBA II results for all 50 patient samples are given in (Supplementary Data
 341 5).



342

343 **Figure 5: PRM transitions detected in patient samples.** A) Sample of a positive patient where
 344 the viral particles were detected by RT-qPCR with a CT value of 17.8. The concentration of the viral
 345 peptide AYNVTQAFGR was estimated to be ~25 fmol (corresponds to 7.5 pmol in the whole swab
 346 sample) by calculating the heavy to light ratio (H/L). B) and C) are patient samples deemed positive
 347 with SAMBA II and Lumira, respectively, which were also confirmed with our method as positives.
 348 D) is a negative patient sample.

349

350 **Discussion**

351 The presented MS-based assay aims to directly detect viral peptides in nasopharyngeal swab
352 samples with faster processing times in a high-throughput manner. The detection is pursued
353 from miniscule amounts of total samples unlike the nucleic acid-based strategies which utilise
354 amplification. This is one of the major reasons attributing to the lower sensitivity of the
355 present MS-based targeted assay compared to nucleic acid amplification-based methods such
356 as PCR and SAMBA. While Lumira does not require amplification, it requires antibodies
357 which can be non-specific and can lead to false positives. In order to achieve more sensitivity
358 higher sample volume needs to be injected onto the system, which poses a challenge when
359 using a nano-flow LC system.

360 Additionally, to provide a boost in sensitivity pre-enrichment methods such as SISCAPA
361 [30], aptamers [31] or bead-based enrichments as utilized by Renuse et.al [15] could be
362 incorporated in the sample preparation workflow, as the viral peptides have very low
363 abundance when measured against a background of human saliva samples rich with high-
364 abundant proteins like Lys C and Amylase. The other reason that contributes towards lowered
365 detection sensitivity of the PRM assay could be assigned to the way the samples were
366 collected and stored. In many of the samples, the traces of food particles and phlegm from
367 individual patients were found, which made sample processing problematic. This highlights
368 the fact that sample collection and storage for MS-based assays should be standardized, such
369 as making sure the nasopharyngeal swab samples are taken by qualified staff, making sure
370 the swabs touch only the back of the throat and the base of the tonsils avoiding any
371 contamination. Also, efforts should be taken towards immediate processing of the samples
372 after collection or stored at -20°C to reduce any protein degradation.

373 Stable isotope standards help in achieving absolute quantification [32]. One such standard is
374 QconCAT (Quantification conCATemer), which is an artificially synthesized protein,
375 generated by concatenation of proteotypic peptides. A heavy labelled QConCAT internal
376 standard enables assessing sampling quality, sample preparation efficacy, instrument
377 robustness, and absolute quantification [16]. Heavy labelled QconCAT synthesized
378 specifically to contain NCAP and SPIKE proteins for SARS-CoV-2 along with other host
379 proteins enabled the absolute quantification of SARS-CoV-2 peptides. Among the patient
380 samples, one sample had been analysed by RT-PCR with a Ct value of 17.8, which indicates

381 a severe viral load. We calculated the amount for the viral NCAP peptide (AYNTQAFGR) to
382 be 25 fmol on column. Assuming that each viral particle contains 300-350 NCAP molecules
383 [33], this indicates that the swab contained approximately 5.25×10^8 viruses. This is in the
384 right order of magnitude with the theoretical calculations conducted by Puyvelde *et al* [16],
385 where a correlation of number of viral particles from measured Ct values of plasmids was
386 attempted. They estimated that a Ct value of 16 would amount to ~20 fmol NCAP/10 μ L
387 sample corresponding to 1.26×10^{10} NCAP copies or 4.2×10^8 viral particles (one RNA per
388 virus) per 10 μ L sample. This shows good correlation of our PRM method with existing
389 methods, as well as enables calculation of viral particles from absolute concentrations of viral
390 proteins. Indeed, more rigorous studies with a greater number of patient samples with
391 standardized sampling protocols are needed to establish a strong peptide concentration-viral
392 particles correlation baseline. Nonetheless, the quantification of these peptides in the
393 nasopharyngeal samples is a step in the right direction to assess not only the prognostic
394 potential of the method but also determining the concentration range of the protein in
395 correlation with the severity of the SARS-CoV-2 disease, which may prove helpful in
396 designing treatments for disease management and thereby reducing complications and
397 hopefully fatalities.

398 **Future Perspectives:**

399 The global response to the Covid-19 pandemic has come a long way since its inception in late
400 2019. Lately, the death toll and the number of SARS-CoV-2 variants arising with the on-
401 going pandemic seem to be under control with the introduction of several vaccines, yet
402 complete global immunization against Covid-19 is still far away. With the world starting to
403 turn slowly towards normality, rigorous testing remains of prime importance until Covid-19
404 is completely eradicated which puts a burden on existing molecular testing methods. The
405 present method could serve as an alternative for fast detection, where such mass
406 spectrometric and chromatographic capabilities are available. With the little requirements for
407 development of an MS-based testing method, it presents with a relative possibility of
408 adapting the existing LC-MS method for detection of the existing and newly emerging
409 SARS-CoV-2 variants as well as multiplexing with other respiratory viruses such as
410 influenza.

411 The sensitivity of the present method has room for improvement by incorporating enrichment
412 methods such as SISCAPA and immunoaffinity in the sample preparation. Additionally,

413 applying automated sample handling to the sample preparation workflow may further reduce
414 the variability and improve the turnover times.

415

416 **Acknowledgements:**

417 We would like to thank Sam Dhesi and Luke Wainwright from the Department of Health and
418 Social Care as well as Perdita Barran for their support. We would like to thank all members
419 of the Laboratory for Biomedical Mass Spectrometry for their support during this project.
420 This work was funded by the UK Department of Health and Social Care. AN is funded by a
421 Marie Skłodowska Curie ITN studentship within the European Union's Horizon 2020
422 research and innovation programme under the Marie Skłodowska-Curie grant agreement No.
423 861316. FS is funded by a BBSRC iCASE studentship (2306774). AG, TH and MT are
424 funded through a Wellcome Investigator Award (215542/Z/19/Z)

425

426 **Author contributions:** AG, AN, TH, FS, AP performed experiments and data analysis. YT
427 provided access to patient samples. AG, AN and MT wrote the manuscript with input of all
428 authors.

429

430 **Conflict of interest: None.**

431 **References:**

- 432 1. WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online:
433 <https://covid19.who.int/> (last cited: 11.03.2022).
- 434 2. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-
435 nCoV and naming it SARS-CoV-2. *Nat. Microbiol.* 2020, 5536–544. 10.1038/s41564-020-
436 0695-z.
- 437 3. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol.*
438 2019 Mar;17(3):181-192. doi: 10.1038/s41579-018-0118-9. PMID: 30531947; PMCID:
439 PMC7097006.
- 440 4. Yoshimoto FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2
441 (SARS CoV-2 or n-COV19), the Cause of COVID-19. *Protein J.* 2020 Jun;39(3):198-216.
442 doi: 10.1007/s10930-020-09901-4. PMID: 32447571; PMCID: PMC7245191
- 443 5. Assennato SM, Ritchie AV, Nadala C, Goel N, Tie C, Nadala LM, Zhang H, Datir R,
444 Gupta RK, Curran MD, Lee HH. Performance Evaluation of the SAMBA II SARS-CoV-2
445 Test for Point-of-Care Detection of SARS-CoV-2. *J Clin Microbiol.* 2020 Dec 17;59(1):
446 e01262-20. doi: 10.1128/JCM.01262-20. PMID: 33051242; PMCID: PMC7771448.
- 447 6. Nicol T, Lefevre C, Serri O, Pivert A, Joubaud F, Dubée V, Kouatchet A, Ducancelle A,
448 Lunel-Fabiani F, Le Guillou-Guillemette H. Assessment of SARS-CoV-2 serological tests for
449 the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated
450 immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG
451 Biotech). *J Clin Virol.* 2020 Aug; 129:104511. doi: 10.1016/j.jcv.2020.104511. Epub 2020
452 Jun 15. PMID: 32593133; PMCID: PMC7295485.
- 453 7. Teymouri M, Mollazadeh S, Mortazavi H, Naderi Ghale-Noie Z, Keyvani V, Aghababaei
454 F, Hamblin MR, Abbaszadeh-Goudarzi G, Pourghadamyari H, Hashemian SMR, Mirzaei H.
455 Recent advances and challenges of RT-PCR tests for the diagnosis of COVID-19. *Pathol Res*
456 *Pract.* 2021 May; 221:153443. doi: 10.1016/j.prp.2021.153443. Epub 2021 Apr 14. PMID:
457 33930607; PMCID: PMC8045416.
- 458 8. Krokhin O, Li Y, Andonov A, Feldmann H, Flick R, Jones S, Stroehrer U, Bastien N,
459 Dasuri KV, Cheng K, Simonsen JN, Perreault H, Wilkins J, Ens W, Plummer F, Standing
460 KG. Mass spectrometric characterization of proteins from the SARS virus: a preliminary

- 461 report. *Mol Cell Proteomics*. 2003 May;2(5):346-56. doi: 10.1074/mcp.M300048-MCP200.
462 Epub 2003 May 29. PMID: 12775768; PMCID: PMC7780042.
- 463 9. Gouveia D, Grenga L, Gaillard JC, Gallais F, Bellanger L, Pible O, Armengaud J.
464 Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent
465 Acquisition Tandem Mass Spectrometry Data. *Proteomics*. 2020 Jul;20(14):e2000107. doi:
466 10.1002/pmic.202000107. Epub 2020 Jun 21. PMID: 32462744; PMCID: PMC7267140.
- 467 10. Ihling C, Tänzler D, Hagemann S, Kehlen A, Hüttelmaier S, Arlt C, Sinz A. Mass
468 Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of
469 COVID-19 Patients. *J Proteome Res*. 2020 Nov 6;19(11):4389-4392. doi:
470 10.1021/acs.jproteome.0c00280. Epub 2020 Jun 23. PMID: 32568543; PMCID:
471 PMC7315851.
- 472 11. Nikolaev EN, Indeykina MI, Brzhozovskiy AG, Bugrova AE, Kononikhin AS,
473 Starodubtseva NL, Petrotchenko EV, Kovalev GI, Borchers CH, Sukhikh GT. Mass-
474 Spectrometric Detection of SARS-CoV-2 Virus in Scrapings of the Epithelium of the
475 Nasopharynx of Infected Patients via Nucleocapsid N Protein. *J Proteome Res*. 2020 Nov
476 6;19(11):4393-4397. doi: 10.1021/acs.jproteome.0c00412. Epub 2020 Aug 19. PMID:
477 32786682; PMCID: PMC7640963.
- 478 12. Singh P, Chakraborty R, Marwal R, Radhakrishnan VS, Bhaskar AK, Vashisht H, Dhar
479 MS, Pradhan S, Ranjan G, Imran M, Raj A, Sharma U, Singh P, Lall H, Dutta M, Garg P,
480 Ray A, Dash D, Sivasubbu S, Gogia H, Madan P, Kabra S, Singh SK, Agrawal A, Rakshit P,
481 Kumar P, Sengupta S. A rapid and sensitive method to detect SARS-CoV-2 virus using
482 targeted-mass spectrometry. *J Proteins Proteom*. 2020 Aug 31:1-7. doi: 10.1007/s42485-020-
483 00044-9. Epub ahead of print. PMID: 33132628; PMCID: PMC7457902.
- 484 13. Gouveia D, Miotello G, Gallais F, Gaillard JC, Debroas S, Bellanger L, Lavigne JP, Sotto
485 A, Grenga L, Pible O, Armengaud J. Proteotyping SARS-CoV-2 Virus from Nasopharyngeal
486 Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window. *J Proteome*
487 *Res*. 2020 Nov 6;19(11):4407-4416. doi: 10.1021/acs.jproteome.0c00535. Epub 2020 Aug 5.
488 PMID: 32697082; PMCID: PMC7640971.
- 489 14. Saadi J, Oueslati S, Bellanger L, Gallais F, Dortet L, Roque-Afonso AM, Junot C, Naas
490 T, Fenaille F, Becher F. Quantitative Assessment of SARS-CoV-2 Virus in Nasopharyngeal
491 Swabs Stored in Transport Medium by a Straightforward LC-MS/MS Assay Targeting

- 492 Nucleocapsid, Membrane, and Spike Proteins. *J Proteome Res.* 2021 Feb 5;20(2):1434-1443.
493 doi: 10.1021/acs.jproteome.0c00887. Epub 2021 Jan 26. PMID: 33497234.
- 494 15. Renuse S, Vanderboom PM, Maus AD, Kemp JV, Gurtner KM, Madugundu AK, Chavan
495 S, Peterson JA, Madden BJ, Mangalaparthy KK, Mun DG, Singh S, Kipp BR, Dasari S, Singh
496 RJ, Grebe SK, Pandey A. A mass spectrometry-based targeted assay for detection of SARS-
497 CoV-2 antigen from clinical specimens. *EBioMedicine.* 2021 Jul; 69:103465. doi:
498 10.1016/j.ebiom.2021.103465. Epub 2021 Jul 3. PMID: 34229274; PMCID: PMC8253671.
- 499 16. Van Puyvelde B, Van Uytvanghe K, Tytgat O, Van Oudenhove L, Gabriels R,
500 Bouwmeester R, Daled S, Van Den Bossche T, Ramasamy P, Verhelst S, De Clerck L,
501 Corveleyn L, Willems S, Debunne N, Wynendaele E, De Spiegeleer B, Judak P, Roels K, De
502 Wilde L, Van Eenoo P, Reyns T, Cherlet M, Dumont E, Debyser G, t'Kindt R, Sandra K,
503 Gupta S, Drouin N, Harms A, Hankemeier T, Jones DJL, Gupta P, Lane D, Lane CS, El
504 Ouali S, Vincendet JB, Morrice N, Oehrle S, Tanna N, Silvester S, Hannam S, Sigloch FC,
505 Bhangu-Uhlmann A, Claereboudt J, Anderson NL, Razavi M, Degroeve S, Cuypers L, Stove
506 C, Lagrou K, Martens GA, Deforce D, Martens L, Vissers JPC, Dhaenens M. Cov-MS: A
507 Community-Based Template Assay for Mass-Spectrometry-Based Protein Detection in
508 SARS-CoV-2 Patients. *JACS Au.* 2021 Jun 28;1(6):750-765. doi: 10.1021/jacsau.1c00048.
509 Epub 2021 May 3. PMID: 34254058; PMCID: PMC8230961.
- 510 17. Zougman A, Selby PJ, Banks RE. Suspension trapping (STrap) sample preparation
511 method for bottom-up proteomics analysis. *Proteomics.* 2014 May;14(9):1006-0. doi:
512 10.1002/pmic.201300553. Epub 2014 Mar 26. PMID: 24678027.
- 513 18. Heunis T, Lamoliatte F, Marín-Rubio JL, Dannoura A, Trost M. Technical report:
514 Targeted proteomic analysis reveals enrichment of atypical ubiquitin chains in contractile
515 murine tissues. *J Proteomics.* 2020 Oct 30; 229:103963. doi: 10.1016/j.jprot.2020.103963.
516 Epub 2020 Sep 6. PMID: 32898700; PMCID: PMC7567960.
- 517 19. Bekker-Jensen DB, Martínez-Val A, Steigerwald S, Rütther P, Fort KL, Arrey TN, Harder
518 A, Makarov A, Olsen JV. A Compact Quadrupole-Orbitrap Mass Spectrometer with FAIMS
519 Interface Improves Proteome Coverage in Short LC Gradients. *Mol Cell Proteomics.* 2020
520 Apr;19(4):716-729. doi: 10.1074/mcp.TIR119.001906. Epub 2020 Feb 12. PMID: 32051234;
521 PMCID: PMC7124470.

- 522 20. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized
523 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol.* 2008
524 Dec;26(12):1367-72. doi: 10.1038/nbt.1511. Epub 2008 Nov 30. PMID: 19029910.
- 525 21. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R,
526 Tabb DL, Liebler DC, MacCoss MJ. Skyline: an open-source document editor for creating
527 and analyzing targeted proteomics experiments. *Bioinformatics.* 2010 Apr 1;26(7):966-8. doi:
528 10.1093/bioinformatics/btq054. Epub 2010 Feb 9. PMID: 20147306; PMCID: PMC2844992.
- 529 22. Mears MJ, Wallace MJ, Yount JS, Fowler LA, Jones PS, Mohler PJ, Wold LE. Viral
530 transport media for COVID-19 testing. *MethodsX.* 2021; 8:101433. doi:
531 10.1016/j.mex.2021.101433. Epub 2021 Jun 30. PMID: 34226865; PMCID: PMC8242216.
- 532 23. Elinger D, Gabashvili A, Levin Y. Suspension Trapping (S-Trap) Is Compatible with
533 Typical Protein Extraction Buffers and Detergents for Bottom-Up Proteomics. *J Proteome*
534 *Res.* 2019 Mar 1;18(3):1441-1445. doi: 10.1021/acs.jproteome.8b00891. Epub 2019 Feb 20.
535 PMID: 30761899.
- 536 24. Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry.
537 *Biochemistry.* 2013 Jun 4;52(22):3797-806. doi: 10.1021/bi400110b. Epub 2013 Mar 27.
538 PMID: 23517332; PMCID: PMC3674507.
- 539 25. Yu A, Zhao J, Peng W, Banazadeh A, Williamson SD, Goli M, Huang Y, Mechref Y.
540 Advances in mass spectrometry-based glycoproteomics. *Electrophoresis.* 2018
541 Dec;39(24):3104-3122. doi: 10.1002/elps.201800272. Epub 2018 Oct 9. PMID: 30203847;
542 PMCID: PMC6375712.
- 543 26. Krieger JR, Wybenga-Groot LE, Tong J, Bache N, Tsao MS, Moran MF. Evosep One
544 Enables Robust Deep Proteome Coverage Using Tandem Mass Tags while Significantly
545 Reducing Instrument Time. *J Proteome Res.* 2019 May 3;18(5):2346-2353. doi:
546 10.1021/acs.jproteome.9b00082. Epub 2019 Apr 12. PMID: 30938160.
- 547 27. Bache N, Geyer PE, Bekker-Jensen DB, Hoerning O, Falkenby L, Treit PV, Doll S, Paron
548 I, Müller JB, Meier F, Olsen JV, Vorm O, Mann M. A Novel LC System Embeds Analytes in
549 Pre-formed Gradients for Rapid, Ultra-robust Proteomics. *Mol Cell Proteomics.* 2018
550 Nov;17(11):2284-2296. doi: 10.1074/mcp.TIR118.000853. Epub 2018 Aug 13. PMID:
551 30104208; PMCID: PMC6210218.

- 552 28. Subsoontorn P, Lohitnavy M, Kongkaew C. The diagnostic accuracy of isothermal
553 nucleic acid point-of-care tests for human coronaviruses: A systematic review and meta-
554 analysis. *Sci Rep.* 2020 Dec 18;10(1):22349. doi: 10.1038/s41598-020-79237-7. PMID:
555 33339871; PMCID: PMC7749114.
- 556 29. Kohmer N, Toptan T, Pallas C, Karaca O, Pfeiffer A, Westhaus S, Widera M, Berger A,
557 Hoehl S, Kammel M, Ciesek S, Rabenau HF. The Comparative Clinical Performance of Four
558 SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. *J Clin Med.*
559 2021 Jan 17;10(2):328. doi: 10.3390/jcm10020328. PMID: 33477365; PMCID:
560 PMC7830733.
- 561 30. Razavi M, Frick LE, LaMarr WA, Pope ME, Miller CA, Anderson NL, Pearson TW.
562 High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast,
563 liquid chromatography-free mass spectrometry. *J Proteome Res.* 2012 Dec 7;11(12):5642-9.
564 doi: 10.1021/pr300652v. Epub 2012 Nov 19. PMID: 23126378.
- 565 31. Richards SL, Cawley AT, Cavicchioli R, Suann CJ, Pickford R, Raftery MJ. Aptamer
566 based peptide enrichment for quantitative analysis of gonadotropin-releasing hormone by LC-
567 MS/MS. *Talanta.* 2016 Apr 1; 150:671-80. doi: 10.1016/j.talanta.2016.01.006. Epub 2016 Jan
568 7. PMID: 26838458.
- 569 32. Schneider LV, Hall MP. Stable isotope methods for high-precision proteomics. *Drug*
570 *Discov Today.* 2005 Mar 1;10(5):353-63. doi: 10.1016/S1359-6446(05)03381-7. PMID:
571 15749284.
- 572 33. Yao H, Song Y, Chen Y, Wu N, Xu J, Sun C, Zhang J, Weng T, Zhang Z, Wu Z, Cheng
573 L, Shi D, Lu X, Lei J, Crispin M, Shi Y, Li L, Li S. Molecular Architecture of the SARS-
574 CoV-2 Virus. *Cell.* 2020 Oct 29;183(3):730-738.e13. doi: 10.1016/j.cell.2020.09.018. Epub
575 2020 Sep 6. PMID: 32979942; PMCID: PMC7474903.